Cailin ConnerPrint | September 22, 2023
Japan's MHLW grants orphan drug designation to treatments designed for fewer than 50,000 patients.
Read More
Cecilia BrownAcute Myeloid Leukemia | September 20, 2023
The retrospective, observational study included adults who received their first allogeneic HSCT during their first remission.
Cecilia BrownChronic Lymphocytic Leukemia | September 20, 2023
Dr. Coombs discusses her journey into oncology, what it’s like to broach the lymphoid and myeloid worlds, and a unique ...
Leah LawrenceLatest Issue | September 20, 2023
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
Othman Al-Sawaf, MDChronic Lymphocytic Leukemia | September 20, 2023
Othman Al-Sawaf, MD, and Nicole Lamanna, MD, debate approaches in this Point | Counterpoint.
Elias Jabbour, MDAcute Lymphoblastic Leukemia | September 5, 2023
September is always an exciting time for SOHO members as the month brings the Annual Meeting in Houston, Texas. 
Cecilia BrownTransplantation & Cellular Therapy | August 29, 2023
Critical drugs used to treat cancer are in short supply in the United States and around the globe.
Blood Cancers Today Staff WritersHodgkin Lymphoma | August 28, 2023
Single-cell analysis has shed new light on the unique biology of classic Hodgkin lymphoma (HL).
Cecilia BrownMantle Cell Lymphoma | August 23, 2023
Researchers conducted the study because patients with TP53-mutated disease “have poor outcomes with standard approaches."
Cecilia BrownMyelofibrosis | August 18, 2023
Researchers conducted an indirect comparison analysis of multiple clinical trials to address the question.
Sagar Lonial, MD, FACPPrint | August 17, 2023
The Blood Cancers Today Editorial Board reflects on the latest news in the field so far in 2023.
Jennifer R. Brown, MD, PhDPrint | August 15, 2023
SOHO President Jennifer Brown, MD, PhD, reflects on the upcoming 11th SOHO Annual Meeting.
Cecilia BrownPrint | August 11, 2023
An open-label phase I study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AVC-201.
Cecilia BrownMyeloma | August 10, 2023
It is approved as a weekly or biweekly subcutaneous injection after an initial step-up phase.
Leah SherwoodMyelofibrosis | August 9, 2023
In June 2023, the manufacturer of the drug initiated XPORT-MF-034, a pivotal phase III clinical trial.
Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | August 4, 2023
Guillermo Garcia-Manero, MD, the 2023 SOHO President-Elect, shares his hopes and goals for the coming years.
Cecilia BrownAggressive B-Cell Lymphoma | August 1, 2023
The application for the approval of epcoritamab is based on results from the phase I/II EPCORE NHL-1 trial.
Leah SherwoodAcute Lymphoblastic Leukemia | July 26, 2023
EMA CHMP adopted a positive opinion recommending the marketing authorization of JZP458.
Cecilia BrownPrint | July 19, 2023
Key advances in understanding and detecting ctDNA could usher in a future with less invasive, but more informative biopsies.
Cecilia BrownAcute Myeloid Leukemia | July 19, 2023
The “effect of gilteritinib was more pronounced” in patients who had detectable MRD than those who did not.
Editorial Board